Goal – Analyse the context in which melanoma-derived cell lines exploit MEK and PI3K signalling to overcome BRAF V600E resistance.
Outcome – Identification of a number of common effects of combination therapy irrespective of the second target as well as specific effects dependant on targeting either MEK or PI3K.
Collaborators – Moffitt Cancer Centre, Tampa, Florida
Goal – To develop a multiplexed assay for the measurement of total expression and regulatory phosphorylation site levels of Estrogen Receptor alpha, Progesterone Receptor beta and HER2 that could be used in classification of Breast tumors.
Outcome – A triple-protein immunoprecipitation
Collaborators Moffitt Cancer Center, Tampa, Florida and Buck Institute for Research on Aging, Novato, California
Goal Profile signalling pathways driving pancreatic ductal adenocarcinomas
Outcome – Analysis of 32 cases shows pathways controlling how cells interact with each other and the tumor stroma are consistently affected in all patients. However, greater heterogeneity was seen in the activity of several key drug targets highlighting the need for personalised treatments for each patient.
Collaborators King’s College Hospital
Goal – Profile Plasma Biomarkers of Cancer
Outcome - 45 serum samples were analyzed in five TMT®10plex sets with 6,150 peptides (mapping to 616 proteins or 310 protein groups) quantified in all samples. Analytical CV = 9.5%, with biological variability at 22% at the peptide level.
Goal – Discovery and validation of biomarkers to assess the response to cMet inhibition and functional inactivation
Outcome - 170 novel biomarkers identified in discovery, BioTag TMT®SRM assay developed to validate the top 28 markers
Collaborators - ProQinase GmBH, Germany & Natural Medical Sciences Institute, University of Tubingen, Germany